A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy

Inclusion Criteria: 1. Age between 18-80 years old, male and female 2. Without anti-cancer treatment before randomization, ECOG score 0-2 3. Estimate to bear at least 4 cycles chemotherapy treatment with normal function of heart, lungs, liver and kidneys. 4. Survival expectation ≥6 months 5. Signed Informed Consent Form, willing to follow all study procedures Exclusion Criteria: 1. Received chemotherapy treatment within 4 weeks before randomization. 2. Current peripheral neuropathy(by chemotherapy, diabetes mellitus, alcoholic disease) and relative symptoms with relevant treatment. 3. Concurrent treatment within 30 days after randomization with the following drugs: Calcium-Magnesium injection, glutathione, and similar ingredients with PerOx Quench (such as polyene phosphatidyl choline). 4. Laboratory tests found not suitable for chemotherapy patients (Absolute neutrophil count \<2.0×10\*9/L\<2,000/mm3\>; or platelet count\<100× 10\*9/L\<100,000/mm3\>; or hemoglobin \<10/dl; or serum total bilirubin \>2 Upper Limit Of Normal (ULN), alanine aminotransferase (ALT)/aspartate aminotransferase (AST)\>3 Upper Limit Of Normal (ULN); or serum creatinine \>1.5 Upper Limit Of Normal (ULN) \<or creatinine clearance rate ≤60ml/min\>）. 5. Pregnancy, lactation and reluctant to using contraception women. 6. Patients with symptomatic brain metastases and other mental disorders could not be self assessment. 7. Alcohol and/or drug abuse or doctors determine compliance's claim. 8. Within a month in other clinical trial subjects. 9. Once into the group of this study, or random within eight weeks before using this product. 10. personnel involved this study. 11. Not completed independent self assessment of patients. 12. Other researchers determine does not fit to participate in this study.